Last reviewed · How we verify
group C
This drug works by inhibiting the renin-angiotensin system to lower blood pressure.
This drug works by inhibiting the renin-angiotensin system to lower blood pressure. Used for Hypertension, Heart failure.
At a glance
| Generic name | group C |
|---|---|
| Also known as | control group, Proof-of-Concept Study, LYN-PLT Formulation C, vaccine made by Hualan Biological Engineering, INC, Placebo |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Drug class | Angiotensin II receptor antagonist |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
It does this by blocking the action of angiotensin II at its receptor, leading to vasodilation and decreased peripheral resistance. This results in a decrease in blood pressure and a reduction in the workload on the heart.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Dizziness
- Headache
- Cough
- Fatigue
- Nausea
Key clinical trials
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- GCF and Saliva Levels of IL-36α in Periodontal Disease (NA)
- Conventional vs Pulsed RF in Coccydynia (NA)
- Evaluation of the Effects of I-PRF and C-PRF on Gingival Phenotype (NA)
- Toddler Biomarker of Nutrition Study (NA)
- Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population
- Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
- Influence of Tamponade on Retinal Shift in Eyes Undergoing Vitrectomy for Rhegmatogenous Retinal Detachment: A Comparison of Gas Versus Silicone Oil in a Pakistani Population (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- group C CI brief — competitive landscape report
- group C updates RSS · CI watch RSS
- Kaohsiung Medical University Chung-Ho Memorial Hospital portfolio CI